Tandem Diabetes Care, Inc.
TNDMHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeTandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. At a $1.18B market cap, Tandem Diabetes Care, Inc. ranks as a small-cap company within healthcare. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.
Market Cap
$1.18B
Beta
1.64
P/E (TTM)
—
P/E (Fwd)
292.82
EPS (TTM)
$-1.37
EPS (Fwd)
$0.06
ROE
-65.7%
ROA
-3.7%
Cash
$570.3M
Total Debt
$734.7M
Free CF
-$20.3M
52W Change
-14.9%
Annual Financials
Cash vs Debt
On the balance sheet, TNDM has $570.3M in cash with $734.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$20.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -65.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $801.2M (2022) to $1.01B (2025), reflecting a 27% increase over the period.
Tandem Diabetes Care, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing TNDM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.